About Us

Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprietary technologies, we are developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options.

Read More

Understand More About

Our Technology

Antibody Discovery Technology

“LP”
Technology

Conjugation
Technology

Know More